Gnudi S, Butturini L, Ripamonti C, Avella M, Bacci G
Servizio di Medicina Interna, Istituto Ortopedico Rizzoli, Bologna.
Ital J Orthop Traumatol. 1988 Jun;14(2):227-31.
The bone density of two groups of patients with osteosarcoma treated with high and low doses of MTX is compared with that of a group of healthy subjects of the same age. Bone density was measured in the radius at the mid point and at the trabecular distal point. In the patients treated with low doses there were differences in bone density as compared with the controls. In those treated with high doses the bone mineral content values were significantly lower than those for the controls (p greater than 0.01) at the trabecular distal point but not at the mid point. The significant reduction in BMC in patients treated with high doses indicated that the osteopaenic effect is dose-dependent. The decrease in density only at the site at which trabecular bone is prevalent shows that MTX acts mainly at the level of this type of bone in accordance with the proven greater sensitivity of trabecular bone to the action of other osteopaenic agents.
将两组接受高剂量和低剂量甲氨蝶呤（MTX）治疗的骨肉瘤患者的骨密度与一组同龄健康受试者的骨密度进行比较。在桡骨中点和小梁远端点测量骨密度。与对照组相比，接受低剂量治疗的患者骨密度存在差异。在接受高剂量治疗的患者中，小梁远端点的骨矿物质含量值显著低于对照组（p>0.01），但在中点处无显著差异。高剂量治疗患者的骨矿物质含量（BMC）显著降低表明骨质疏松效应具有剂量依赖性。仅在小梁骨占优势的部位出现密度降低，表明MTX主要作用于这类骨水平，这与已证实的小梁骨对其他致骨质疏松药物作用的更高敏感性一致。
